Loading…

Zimmer BiometZBHCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Major maker of orthopedic joint-replacement implants, spine, sports medicine and surgical robotics (ROSA) products.

Momentum leader 80
Mkt cap
$19.6B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$272M
20-day average traded
Fwd P/E
11.7×
forward earnings
ROIC−WACC
-1.4 pp
WACC 7.0%
Hurdle
+4 pp
Req g minus delivered
Official | Implied
BBB / BBB+
agencies · bond market
Next earnings
85 days
11 Feb 2027
Close · USD$103.32
1D+1.2%
1W-3.9%
1M+7.6%
3M+4.4%
6M+21.3%
YTD+15.5%
1Y+17.5%
ATR %3.2%
Beta0.46
52w lowhigh8.2% off high

What Zimmer Biomet does

Major maker of orthopedic joint-replacement implants, spine, sports medicine and surgical robotics (ROSA) products.

Sells implants to hospitals and surgery centres, with each operation drawing on instrument trays and implant sets the company supplies and its representatives attend, so revenue is earned case by case; replacement knees and hips are the core. It was formed by the 2015 Zimmer and Biomet merger and spun off ZimVie (dental and spine) in 2022.

Products and services

  • Knee & hip reconstruction
  • ROSA surgical robotics
  • Sports medicine, extremities, trauma

Customers

  • Orthopedic surgeons
  • Hospitals
  • Ambulatory surgery centers

Where it sits in the supply chain

  • Healthcare
  • Medical devices
  • Orthopedic implants and surgical…

What could go right

  • ROSA robotic placement growth
  • Ambulatory surgery center shift

What could go wrong

  • Implant pricing pressure
  • Market-share loss to Stryker's Mako platform

Moat: narrow (installed base, switching costs, brand). Long-standing surgeon relationships and installed robotic base in a concentrated orthopedic implant market.

Headquarters: Warsaw, Indiana, USA · Founded: 1927 · Employees: 17,000

Named competitors

Zimmer Biomet at a glance

Size Zimmer Biomet (ZBH) is a United States Health Care company (Medical Specialties) with a market value of $19.6B, the 498th largest of 3,085 United States companies the cockpit tracks. Shares closed at $103.32 on 18 Nov 2026.

Performance Over six months the shares gained 21.3%, against +26.2% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 7.0% over the last twelve months (peer median +7.1%); the operating margin is 16.4% (peer median 17.4%).

Valuation It trades at 11.7× forward earnings against a peer median of 28.0× (cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.4 points below its cost of capital (7.0% WACC).

Credit Zimmer Biomet has 16 bonds outstanding ($7.28B), rated BBB by the agencies and trading like BBB+ at a weighted spread of 96 bp.

Short interest Short interest is 4.2% of the free float (30 Oct 2026).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011012013021 May 202621 Aug 202618 Nov 2026Peer median 124ZBH 121
Six months, rebased to 100: Zimmer Biomet against the median of its 20 peers (local-currency closes).

Zimmer Biomet financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$8.57B$8.23B$7.68B$7.39B$6.94B
Revenue growth—+7%+4%+7%—
Gross profit$5.26B$5.02B$4.82B$4.66B$4.34B
EBITDA$2.51B$2.42B$2.48B$2.34B$2.13B
Net income$767M$705M$904M$1.02B$231M
Free cash flow$1.29B$1.17B$1.06B$979M$838M
Capital expenditure$726M$577M$597M$689M$512M
Total debt$7.50B$7.75B$6.39B$6.00B$5.92B

Quarterly statements and history in the cockpit →

Zimmer Biomet competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%GHSOONSRTSTMNRVTYCOLO-B4543DIMSTE688271GKOSLENSKARTWSTBAX7733PENSNDXCMILMNBIMZBH6-month return →1-month return →
Up and to the right = strong over both horizons. Zimmer Biomet is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×50×100×150×SOONSRTSTMNRVTYCOLO-B4543STE688271GKOSLENSKARTWSTBAXPENDXCMBIMZBHRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zimmer Biomet is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%SOONSRTSTMNRVTYCOLO-B4543DIMLENSKARTWSTBAX7733PENSNDXCMBIMZBHGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zimmer Biomet is the large dot.

Zimmer Biomet competitors and peer comparison

Head to head with its named competitors (ZBH vs SYK vs JNJ vs SN..L)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zimmer Biomet ZBH$19.6B+21%+7%16%11.7×7.4%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
Smith & Nephew SN..L$12.6B+1%+2%17%14.2×11.1%
Medtronic MDT$129B+30%+10%20%16.8×9.1%

How Zimmer Biomet compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zimmer Biomet against its 20 peers (data as of 18 Nov 2026)
MeasureZBHPeer medianRank in peer set
1-month return+7.6%+5.5%7th highest of 21
6-month return+21.3%+26.2%8th lowest of 21
Distance from 52-week high-8.2%-11.1%9th highest of 21
Revenue growth (TTM)+7.0%+7.1%11th highest of 21
Operating margin16.4%17.4%8th lowest of 21
Forward P/E11.7×28.0×cheapest of 20
Growth the price implies (Req g, 7 yrs)7.4%16.2%4th least demanding of 18
Growth delivered (Del g)+3.2%+8.3%3rd lowest of 18
Hurdle (Req g minus delivered)+4.2 pp+5.5 pp9th least demanding of 18
ROIC minus cost of capital-1.4 pp+2.2 pp8th lowest of 21
EV / EBITDA10.6×20.2×3rd cheapest of 18
Net debt / EBITDA2.8×0.8×3rd most indebted of 18
Bond spread96 bp99 bp5th tightest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zimmer Biomet ZBHUnited States$19.6B+21%+7%16%11.7×7.4%+3.2%
Guardant Health GHUnited States$19.6B+26%+42%-39%n/an/an/a
Sonova SOON.SWSwitzerland$19.8B+40%-6%23%25.3×6.0%+6.7%
Sartorius SRT.DEGermany$19.9B+26%+4%18%43.0×25.6%+8.7%
Straumann STMN.SWSwitzerland$20.4B+20%+2%21%32.9×16.2%+12.8%
Revvity RVTYUnited States$17.0B+61%+5%16%26.2×26.4%-5.5%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%20.0×-2.1%+8.3%
Terumo 4543.TJapan$24.0B+32%+15%17%27.8×8.8%+13.0%
Sartorius Stedim Biotech DIM.PAFrance$24.2B+32%+4%19%45.7×33.4%+9.2%
Steris STEUnited States$25.2B+21%+8%20%21.9×14.0%+13.8%
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%45.7×n/an/a
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%
West Pharmaceutical Services WSTUnited States$28.1B+32%+13%23%40.2×25.8%+7.4%
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Dexcom DXCMUnited States$30.8B+16%+13%24%28.0×19.6%+19.3%
Illumina ILMNUnited States$31.8B+48%+6%21%35.2×27.2%+6.0%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%

Zimmer Biomet bonds and credit

Zimmer Biomet has 16 bonds outstanding with $7.28B face value. The agencies rate it BBB; its bonds trade like BBB+. Weighted yield 5.05%, a spread of 96 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Zimmer Biomet's main competitors?
Named competitors: Stryker Corporation (SYK), Johnson & Johnson (JNJ), Smith & Nephew (SN..L), Medtronic (MDT). The cockpit's measured peer set (industry) also includes Guardant Health (GH), Sonova (SOON.SW), Sartorius (SRT.DE), Straumann (STMN.SW), Revvity (RVTY), Coloplast A/S (COLO-B.CO).
Is Zimmer Biomet expensive compared with its peers?
On forward p/e it trades at 11.7× against a peer median of 28.0×, cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Zimmer Biomet stock performed?
Over six months to 18 Nov 2026 the shares returned +21.3% against +26.2% for the median peer; over one year +17.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.